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Abstract
Methylation is a fundamental mechanism used in the biological system to modify the structure and
function of biomolecules such as proteins, DNA, RNA, and metabolites.1 Methyl groups are installed by a
large and diverse class of S-adenosyl-L-methionine (SAM)-dependent methyltransferases (MTases), which
transfer the sulfonium methyl group of SAM to either carbon, nitrogen, oxygen, or other heteroatoms on
biomolecules.2 Dysregulated MTase activity contributes to numerous diseases, including cancer, metabolic
disorders, neurodegenerative diseases.3 Presently, there is intense interest in pursuing MTases as therapeutic
targets for the treatment of the
aforementioned diseases.
A
The human MTase family has
more than 200 members.4
However, a large fraction of this
family
remains
poorly
B
characterized in terms of their
endogenous substrates and
biological functions. The need
for innovative chemical probes
to evaluate MTase function in
the native biological matrix
becomes apparent.5–8 In this
current
project,
we
are
developing an activity-based Fig.1. SAM analog for the profiling of MTase activity. A. Chemical
structure of probe 1; B. General scheme of the labeling and capture
protein profiling (ABPP) probe
strategy.
to directly investigate MTase
activity in a complex biological sample. This probe (probe 1, Fig. 1A) is a structural analog of SAM with
several major components: 1) a methylated nitrogen “warhead” mimics the positively charged sulfur in
SAM;9 2) a photocrosslinkable azido group for the covalent modification of the target enzyme; 8 3) a biotin
tag for the subsequent affinity capture by streptavidin beads. The general scheme of the labeling and
enrichment strategy is shown in Fig.1B. This strategy will selectively enrich for the active MTase content
in a complex cellular context. Side-by-side comparison of functional MTase profiles under different
physiological and pathological conditions, combined with proteomics analysis, should unwind the intricate
interaction loops between human MTases and various cellular pathways, as well as empower the better
manipulation of these enzymes for therapeutic purposes.
Our original synthetic plan started with commercially available 8-bromoinsoine and acetyl protection of
the 2', 3', and 5'-hydroxyl groups of the ribose ring (Fig. 2A).6 It was expected that after the installation of
the azido group and the coupling with the biotin tag, the 5’-O-acetyl group could be selectively deprotected
to enable the subsequent “warhead” installation. However, the selective deprotection using a published
protocol was proven to be unsuccessful.6 Instead of the mono-deprotected probe 2, the mono-protected
probe 3 was obtained. In the revised synthetic plan, the 2' and 3'-OHs were protected as an acetonide. 10 The
5'-OH can then be selectively protected by the acetyl group. The azido group was readily installed at 8-
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position
with
NaN3.
The
A
biotin tag was
tethered to the
C6-position of
the adenine ring
through a 1,6hexadiamine
linker.9,11 The
B
5'-OH can then
be selectively
deprotected to
afford
the
photocrosslinkable adenosine
derivative probe
4 (Fig. 2B). The
later stage of the
synthesis
focuses on the
Fig.2. Synthetic plans for probe 1. A. Original plan involves the tri-O-acetylation of the
installation of
hydroxyl groups on the ribose ring. However, the selective deprotection of 5'-OH was
the “warhead”.
challenging; B. Revised plan features the selective protection/deprotection of 5’-OH.
The 5'-OH was
activated as a mesylate, which can then be replaced by a methylamino group.6 The subsequent reductive
amination with tert-butyl (S)-2-[N-(tert-butoxycarbonyl) amino]-4-oxobutanoate allowed the “warhead” to
be fully incorporated into the structure. Finally, the global deprotection should provide the desired SAM
analog, probe 1. We are still in the process of finalizing the last step of the synthesis.
In parallel to the synthetic effort, we also established and optimized the photoaffinity labeling and affinity
enrichment assays. Recombinantly expressed and purified human euchromatin histone lysine
methyltransferase 1 (EHMT1) was used for the initial assay development. Several parameters such as
irradiation time, probe dosage, and
elution conditions were fine-tuned to
ensure accurate profiling of active
A
enzymes. The protein was incubated
with probe 3, followed by UV
irradiation to trigger the covalent
conjugation (Fig. 3A).8,12 The unbound
free probes were then filtered off.
Subsequently, streptavidin beads were
introduced to the sample to capture the
biotinylated
protein.
Ultimately,
EHMT1 was eluted off the beads and
analyzed by western blot using antiB
biotin antibody. EHMT1 was only
strongly labeled by probe 3 at high
micromolar concentrations (Fig. 3B,
left). We reasoned that probe 3 is an Fig.3. Photoaffinity labeling and affinity capture of recombinant
proteins using synthetic probe. A. Schematic representation of the
adenosine analog rather than a SAM
labeling and enrichment protocols; B. Western blots showing the
analog. It may demonstrate selectivity
labeling of EHMT1 (left) and ADA (right) with probe 3. The
towards adenosine-binding proteins.
biotinylated proteins were detected with anti-biotin antibody.
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Indeed, probe 3 labeled adenosine deaminase (ADA) in a concentration-dependent manner (Fig. 3B, right).
Even at the lowest probe concentration, ADA can still be labeled and enriched. The labeling can be
competed off using a known ADA inhibitor, suggesting the on-target effect of the probe.
The labeling strategy was also applied to cell lysates. It has the advantage of enriching the active enzymes
independently of protein abundance, allowing the capture of dynamic enzyme activity changes in response
to environmental or cellular stimuli.
In the current study, the facile synthesis of SAM analogs was developed. Photoaffinity labeling and
affinity enrichment protocols were developed. The probes were able to label recombinant proteins, and
demonstrated target selectivity. The synthesis of probe 1 will be completed. These innovative chemical
probes will be used to profile MTase activity in their native matrix to better understand their roles in
different cellular events.
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1. Introduction and Background
1.1 Epigenetic regulation of gene expression
Epigenetics, a term first used by C.H. Waddington in 1942, is defined as the changes in gene
expression without changing the genetic code of the organism. 13 These changes are achieved
through epigenetic modifications as well as chromatin remodeling, which regulate the accessibility
of specific genes to the transcriptional machinery.14 The three major epigenetic changes include:
1) covalent modifications at the DNA level, namely, DNA methylation; 2) covalent modifications
of the histone N-terminal tails such as methylation, acetylation or phosphorylation; and 3) noncoding RNA regulations such as siRNA and miRNA. 15 All of these changes orchestrate the access
of DNA, which serves as the main interface between environmental cues and transcription
activation/suppression. For the scope of the current study, the following discussion will focus on
DNA methylation and histone modifications.
In eukaryotic cells, DNA is wrapped around histone proteins to form nucleosomes, which are
considered the basic units of chromatin.16,17 The packaging of DNA into chromatin controls the
accessibility of genetic materials. DNA methylation, more specifically, the methylation of cytosine
residues in the promoter region of genes has profound consequences in gene transcription. Simple
methylation at the 5-position of cytosine at CpG islands prevents the binding of transcription
factors to the promoter region, ultimately leading to gene silencing. 18 The significance of 5methylcytosine (5mC) in transcription silencing, genomic imprinting and cellular differentiation
has been well established.19,20 This is why sometimes 5mC is referred to as “the fifth base” of the
genome.
The histone octamer is composed of two copies of each of the core histones H2A, H2B, H3,
and H4.16,17,21 The N-terminal tails of histones are prone to posttranslational modifications (PTMs)
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including, but not limited to, methylation, acetylation, phosphorylation and SUMOylation. 22
Accumulating evidence suggested that the N-terminal tails of histones interact with neighboring
nucleosomes to affect the overall chromatin structure.21 In addition to regulating the binding
affinity of DNA to histones,23 the PTMs also serve as the docking sites to recruit effector proteins
resulting in chromatin remodeling, transcription regulation, and DNA repair. 24,25 Among all the
histone PTMs, lysine acetylation was the first to be reported. 26 The addition of acetyl group to
lysine side chain -amino group, which is positively charged under normal physiological
conditions, neutralizes the positive charge and weakens the interactions between histone and
negatively charged DNA backbone. Consequently, chromatin relaxation occurs to allow
transcription activation.27 The acetylation can be reversed for chromatin condensation, which is
closely associated with transcription silencing.
Histone methylation, in contrast, is more complex than acetylation. It occurs on lysine and
arginine residues. Methylation does not change the charges of these amino acids. To make it more
complex, lysines can be mono-, di- or tri-methylated, and arginines can be mono- or di-methylated
(either symmetrically or asymmetrically).28,29 Furthermore, the functional consequences of histone
methylation rely on the methylation degree and methylation site. For example, the trimethylation
of histone H3 lysine 27 (H3K27me3) by polycomb group proteins is closely associated with
transcription silencing.30 On the contrary, the trimethylation of histone H3 lysine 4 (H3K4me3) is
a hallmark of transcription activation via the recruitment of RNA polymerase II elongation
factors.31,32
Epigenetic changes are heritable and affected by various factors such as development, exposure
to environmental chemicals, administration of drugs and other pharmaceuticals, aging, and
diet.33,34 For example, during the Dutch famine of 1944-1945, malnutrition ran rampant through
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population of the Netherlands. When examined at the DNA levels, it was noticed that there
appeared to be dysregulation of the DNA methylation patterns in the survivors due to prenatal
exposure to the famine.35
1.2 Epigenetic modification proteins and enzymes and their roles in diseases
The dynamic and reversible epigenetic landscape is maintained by a group of proteins and
enzymes including “writers”, “erasers” and “readers”.36,37 The “writer” enzymes are responsible
for the introduction of covalent modifications to DNA nucleobase or histone amino acids. DNA
methyltransferases (DNMTs) and histone acetyltransferases (HATs) are examples of the “writers”.
“Erasers”, on the other hand, are dedicated for the removal of chemical modifications from DNA
or histone proteins. Histone deacetylases (HDACs) and histone lysine demethylases (KDMs)
represent the “eraser” enzymes.23

“Reader” proteins specialize in the recognition and

interpretation of epigenetic marks. Specialized domains in chromatin modifiers act as “readers”
such as bromodomains (BRDs)38 and plant homeodomains (PHDs).39
Growing evidence demonstrated that the epigenetic proteins work coordinately to regulate
gene transcription, and defects of these proteins play important roles in disease initiation and
development. On one hand, altered functions caused by mutations or altered protein abundance of
an epigenetic regulator protein may directly impact gene expression, leading to diseases such as
cancers. Alternatively, an aberrant gene expression may be driven by an upstream factor, and
epigenetic proteins serve as mediators in this signaling cascade. 40 The reversible nature of
epigenetic modifications suggest that any dysregulation can be restored by drugs targeting the
epigenetic regulators.37,41
The last few decades witnessed tremendous efforts in pursuing “writers”, “erasers”, and
“readers” as viable therapeutic targets. However, the success stories were scarce. The DNMT
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inhibitor, azacitidine, was the first epigenetic drug to be approved by FDA for the treatment of
myelodysplastic syndrome.42 Vorinostat, a small molecule HDAC inhibitor, was approved for
cutaneous T-cell lymphoma.43 It is important to point out that these success relied solely on
phenotypic observations before the mechanism of action (MOA) was discovered. Several DNMT
and HDAC inhibitors have been marketed later on, most of which are analogs of azacitidine or
vorinostat.44 Since then, the drug discovery focus has been shifted to other epigenetic targets. For
example, the once considered “undruggable” BRDs became the highly sought-after targets for
epigenetic drug discovery, owing to their implications in cancers and other diseases. 45 A handful
of BRD inhibitors have become clinical candidates for cancers, 46,47 diabetes,46 and
atherosclerosis.48 The current bottlenecks for epigenetic drug discovery include isoformselectivity, substrate selectivity, and combination therapy, among the others. 44,49,50 With the rapid
progress of “oimcs” analysis, phenotypic assays as well as structural biology studies, it is
anticipated the discovery and development of epigenetic drugs will be greatly accelerated. 44,51,52
1.3 Methyltransferases
Methyltransferases (MTases) are a group of epigenetic writer enzymes that are responsible for
the methylation of nucleobases and histone protein amino acids. Methyltransferases most often
methylate lysine and arginine of histone proteins, and cytosines in DNA. In the process of
methylation MTases transfer a methyl group to their target from S-adenosyl-L-methionine (SAM)
transforming it into S-adenosyl-L-homocysteine (SAH).
1.3.1

DNA Methyltransferases

DNA methyltransferases (DNMTs) are a family of enzymes that are responsible for the
methylation of the 5 position of cytosines into 5-methylcytosine (Fig. 1.). 53 The mammalian
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Figure 1. A. DNMTs methylate the 5 position of cytosine. B. DNA that is unmethylated on the promoter region easily allows
transcription factors to interact and transcribe the gene. When methylation occurs on the promoter region the transcription
factors cannot easily interact with the DNA and prevents transcription of the gene.

DNMT family is comprised of DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L. If the
methylation to the DNA occurs on a cytosine that is located in the promotor region of a gene could
cause the gene to be silenced.
DNMT1, DNMT3A, and DNMT3B are responsible for the methylation of cytosines in the
DNA.19 DNMT1 functions by selectively hemimethylating DNA. Hemimethylation is methylation
of just one of the two complementary strands of DNA. DNMT3A/3B are de novo DNA MTases,54
which is attributed to their activity in methylation during embryogenesis. An up regulation of any
one of these three DNMTs can lead to hypermethylation of the genome. Hypermethylation of the
p16 tumor suppressor gene has been linked to non-small cell lung cancer (NSCLC). 55 The
upregulation of the three above-mentioned DNMTs have been observed in myeloid leukemia. 39,52
Hypermethylation of tumor suppressor gene p15 was suggested as the cause for the myeloid
leukemia. Mice embryos that have the gene for DNMT1, DNMT3A, or DNMT3B deleted become
unviable and expire before development.
Instead of methylating DNA, DNMT2 specifically methylates the 38 th cytosine on tRNA.35
DNMT2 is primarily localized in the cytoplasm of mammalian cells, instead of the nucleus like
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other DNMTs. DNMT2 knock out mice tRNAs have a higher rate of amino acid substitutions,
leading to the incorrect codon recognition.54,55
The DNMT family is round out by DNMT3L,56 which lacks the same C-terminal domain
that gives DNMT3A and DNMT3B their activity. DMNT3L does not methylate DNA or RNA
like the rest of the DNMTs. It has no catalytic activity all by itself. It has been reported that the
activity of DNMT3A or DNMT3B is increased when they interact with DNMT3L. 54
1.3.2

Histone Methyltransferases

There are 2 classes of histone MTases, lysine MTase (KMT) and arginine MTase (PRMT). 57
Both of these MTases are responsible for the methylation of specific lysine or arginine residues
in histone proteins’ tails. Lysine can be mono, di, or trimethylated by KMTs (Fig. 2.), while
arginine can only be mono or dimethylated by PRMTs. Methylating histone tails does not always
lead to suppressed gene transcription like it does for DNA methylation. Methylation of histone
tails can activate or suppress gene expression. The change in gene expression is dependent on the
degree and location that the methylation occurs to.
Some residues, such as H3K4, H3K9, H3K27, H3K36, H3K79, and H4K20 are more likely
to be methylated by KMTs. Euchromatin Histone Methyltransferase 1 (EHMT1), also known as

Figure 2. KMTs with methylate the amine on Lysine. This methylation can occur in
monomethylation, demethylation, or trimethylation. This methylation does not change the
charge of the lysine residue, instead location and degree of methylation lead to the change in
gene expression.
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G9a-like protein (GLP),1 is a well-studied KMT that most often mono- or dimethylates H3K9.
EHMT1 has been observed to methylate other proteins, such as H3K27 and even itself. Mono
methylation of the K370 has been linked to the suppression of tumor suppressor gene p53. 58
Esophageal cancer specifically has been linked to an overexpression of EHMT1, and levels of
EHMT1 present have been linked to physical characteristics of the tumors. 59
Enhancer of Zeste Homolog 2 (EZH2) is a KMT that when up regulated has been linked to
poor prognosis of colorectal cancer.57,60 EZH2 is the core part of Polycomb Repressor Complex
2 (PRC2), a group of enzymes that aid in the methylation of H3K27. (Fig. 3. A.) Trimethylation
of H3K27 has been linked to gene silencing due to a subsequent recruitment of DNMTs that
perform de novo methylation in cancer cells.57,60 Because of this, EZH2 has also been linked to
many other cancers such as pancreatic cancer, prostate cancer, lung cancer, and breast cancer. 60

A

B

Figure 3. A. Methylation of H3K27 by EZH2 leads to the suppression of the genes.
B. In the absence of EZH2 methylation of H3K27 cannot occur, this leaves the
genes active.
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Labs like Wei Qi et al have worked on synthesizing small molecule inhibitors to prevent
hypermethylation of H3K27 caused by EZH2 as a treatment for colorectal cancer. 61
Another important KMT is the Disruptor of Telomeric silencing 1-Like (DOT1L). 62 DOT1L
gene knock out has been observed in yeast, flies, mice, and humans, a commonality between all
of these samples is that H3K79 is always unmethylated.1,63 This leads to the conclusion that
DOT1L is the only KMT that can mono, di, or trimethylate H3K79. This is important to know
because dysregulation of DOT1L leads to hypermethylation of H3K79 and can lead to Mixed
Lineage Leukemia (MLL). In addition to a link to MLL, DOT1L is partially responsible for
recruiting DNA repair proteins such as tumor suppressor p53-binding protein 1 (53BP1). 38 If
there are lower levels of H4K20me present in the cells then 53BP1 will rely on H3K79me for
recruitment. If DOT1L is downregulated then the 53BP1 no longer can repair the DNA.

Figure 4. Type I, II, and III RMTs can perform the monomethylation of an
arginine residue on a histone tail. Type I RMTs can also perform the
asymmetric dimethylation reaction while Type II performs the symmetric
dimethylation reaction.
16

PRMTs are a family of eleven MTases that are placed into three groups. The first is Type I
which contains Protein arginine MTase 1 (PRMT1), PRMT2, PRMT3, PRMT4, PRMT6, and
PRMT8.62 Type I PRMTs catalyze the formation of monomethylated arginine as well as
asymmetric demethylated arginine (Fig. 4.). The second group, Type II, contains PRMT5 and
PRMT9; which catalyze the formation of monomethylated arginine as well as symmetric
demethylated arginine. The final group of PRMT is Type III which contains PRMT7 with a
selectivity for the formation of monomethylated arginine over the formation of symmetric
demethylated arginine.64 Non-Hodgkin’s Lymphoma, as well as other various cancers, have been
linked to an upregulation in PRMT5.65 In early stage clinical trials, GSK3326595, a potent
PRMT5 inhibitor developed by GSK, has shown the ability to inhibit tumor growth. 1,35
1.4 Small Molecule MTase Probes

A

B

D

C

Figure 5. A. L. Comstock lab’s probe B. Cyclized probe product C. Substrate-probe complex D. Substrateprobe-biotin reaction.
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SAM based probes have been developed for a better understanding of MTases. Many of the
probes currently available target substrates of MTases instead the MTases themselves. These
powerful small molecule probes have greatly expanded the substrate range of various MTases.
Van Mai et al created a SAM based MTase probe (Fig. 5. A.) that was used in a proof-ofconcept study to label MTase substrates.66,5 The probe has 2 functionalities that separate it from
SAM. The first is an ethyl iodide functional group that replaces the methyl group on the
warhead, and the second is the long linker group with an alkyne group on it. The ethyl iodide
group has the iodine that is a good leaving group. The departure of iodine causes an
intramolecular cyclization reactionto form an aziridine ring. When the cyclized probe interacts
with a MTase and its target substrate, instead of adding a methyl group to the substrate, the entire
probe is covalently connected to the substrate. Following this the substrate-probe complex can be
reacted with biotin-azide via a click reaction. The substrate-probe-biotin complex can then be
separated from the cell lysate using streptavidin beads. The captured protein can then be
analyzed by mass spectrometry to determine what targets a specific MTase would have.
In the proof-of-concept study Van Mai et al tested if the probe could covalently bind to
AcH4-21, a known target of PRMT1, in the presence of this MTase. The probe was incubated
with AcH4-21 in a buffer solution. PRMT1 was added to the solution then given time to catalyze
the addition of the probe to AcH4-21. The reaction could be quenched, then the PRMT1 could be
denatured with heat, and then biotin-azide could be conjugated to the probe-AcH4-solution for
separation. Following the click reaction, the probe-AcH4-21-biotin complex would be separated
from the solution and then analyzed. Van Mai et al concluded that this probe could be used to
study MTase’s substrates.
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Figure 6. A. The SAM based probe created by E. Weinhold lab. B. How the probe modifies the DNA. The
Methyltransferase used in this study was M.TaqI which selectively Methylates adenosines that are located in
TCGA regions of DNA.

Another SAM based probe was developed by Christian Dalhoff1 et al (Fig. 6. A.), this probe
was created to study DNMTs.7 Instead of acting like the previous probe and adding the entire
probe to the substrate, this probe works by adding an acetyl group instead. This probe is SAM
aside from one functional group change, the methyl is changed to a 2-butyne. The goal of this
probe is to acetylate the DNA instead of methylating it. (Fig 5. B.) A proof-of-concept study was
run with this probe, again M.TaqI and R.TaqI were used to determine if this probe could modify
the DNA. Christian Dalhoff1 et al tested this probe by incubating one sample with the probe,
DNA, and M.TaqI and then denatured the M.TaqI and incubated the sample with R.TaqI. In the
second sample DNA was incubated with M.TaqI, then the M.TaqI was denatured and it was then
incubated with R.TaqI. Following this the samples were run on SDS page gels. Christian
Dalhoff1 et al found that these probes were successful at modifying the DNA and that the
M.TaqI was able to accommodate a larger group than a methyl.
1.5 MTase Inhibitors
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Figure 7. A. A-366 a selective EHMT1 inhibitor made by Abbvie. B. Azacitidine is an FDA approved DNMT1
inhibitor for the treatment of Myelodysplastic Syndrome. C. EPZ004777 a DOT1L inhibitor created by
Epizyme as a treatment for Mixed Lineage Leukemia (MLL).

Inhibitors have been developed to overcome the dysregulation of MTases in specific disease
states. MTase inhibitors have been developed to knock down or knock out specific MTases to
attempt to treat specific diseases. Examples of some of these inhibitors are Azacitidine, A-366,
and EPZ004777.
On May 19th, 2004, Azacitidine (Figure 7A), 67 a DNMT1 inhibitor, was approved by FDA for
the treatment of myelodysplastic syndrome as well as myeloid leukemia. 51 As a cytidine analog
prodrug, azacitidine can be incorporated into DNA to become active. When DNMT1 attempts to
methylate the azacitidine that have been incorporated into the DNA, a coupling reaction will occur
to covalently tethered the DNMT1 in place. DNMT1 being covalently bound to azacitidine
prevents DNMT1 from further performing its function. The inactivation of DNMT1 corrected the
dysregulation that otherwise leads to hypermethylation of the tumor suppressor genes. (reference?)
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A-366 is an inhibitor that was discovered by AbbVie, through high throughput screening. A366 binds with selectivity to Euchromatin methyltransferase 1 (EHMT1) and Euchromatin
methyltransferase 2 (EHMT2) (Fig. 7. B.).68 A-366 specifically has been used in early studies as a
treatment for leukemia. Being able to selectively inhibit specific MTase makes A-366 a good drug
candidate. In this study A-366’s ability to inhibit the dimethylation of H3K9 was compared
withUNC0638. H3K9me2 was chosen because the level of this epigenetic mark is highly linked
to the action of EHMT1/2. UNC0638 was selected because it was a proven EHMT1/2 inhibitor
with unfavorable off target. Both compounds were incubated with MCF-7 and MDA-MB-231
cells, two breast cancer cell lines. Subsequently, the level of H3K9me2 was evaluated by western
blot. Both inhibitors demonstrated comparable ability to reduce the level of H3K9me2, primarily
through the inhibition of EHMT1/2.
EPZ004777 (Fig. 7. C.) is a DOT1L inhibitor that was discovered by Epizyme to prevent
H3K79 methylation. DOT1L is the only known MTase to methylate H3K79. 63 When DOT1L is
dysregulated, it can lead to the hypermethylation of H3K79 which has been linked to Mixed
Lineage Leukemia (MLL).38,57 MLL is an aggressive cancer that accounts for 70% of infant
leukemias. In this study varying concentrations of EPZ004777 were given to MLL cells, and the
level of H3K79me2 was assessed by western blot. With increasing concentrations of EPZ004777,
the level of H379me2 was gradually decreased.
1.6 Activity-based Protein Profiling
The human genome encodes 20,000~25,000 genes.69 Based on alternative promoters or
alternative splicing as well as mRNA editing, it is estimated that the transcriptome harbors
~100,000 transcripts.70 The complex increases exponentially via Post Translational Modifications
(PTMs). The proteomes may contain more than 1,000,000 proteins. 71 The functional assignment
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of these proteins in the so-called “post-genomic era” can be challenging. 72 The classical method
to study protein function involves the recombinant expression and purification of the protein target,
followed by characterization using in vitro assays. Although useful, it is only applicable to proteins
that can be expressed recombinantly. Furthermore, some proteins exist in large protein complex
endogenously. Upon isolation, they may lose activity entirely. And for some proteins, activity
assays are not readily available.
Proteomic analysis has been increasingly recognized as a powerful approach to investigate
protein abundance on a large scale.73 In cells, the protein function can be regulated by several
factors such as PTMs, endogenous protein binding partners, and endogenous inhibitors. 74 It is
critical to point out that these above-mentioned factors may alter protein function/activity without
changing protein abundance. Thus, abundance-based proteomic studies may only provide indirect
information about protein function.

Figure 8. Proteome can be incubated with ABPP probe to selectively target active enzymes only. ABPP probes can have a
florescent group on them to visualize active enzymes. ABPP could also have a biotin group on them to allow for binding
to streptavidin beads to separate bound proteins from cell lysate and then MS analysis can be run to determine which
enzymes were active.
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Recent studies suggested that the functional interrogation of enzymes in complex native matrix
can be accomplished by activity-based protein profiling (ABPP), pioneered by Ben Cravatt’s group
at the Scripps Research Institute.75 ABPP utilizes active site-directed small molecule probes to
directly confer the functional state of a particular enzyme in a complex biological sample. 76,77 The
key player in ABPP is the small molecule probe which normally has three major components: 1)
a reactive group (or “warhead”) that targets the active site of an enzyme; 2) a tag that allows the
visualization or affinity capture of the active enzyme; 3) a liner that connects the “warhead” with
the tag. The ABPP probes label the active enzyme, but not the inactive or inhibitor-bound ones.
Comparison of the labeling intensity and labeling pattern in normal cells/tissues vs disease
cells/tissues will reveal the role a specific protein plays in certain physiological or
pathophysiological process, and may also suggest potential therapeutic targets for drug discovery
(Fig. 8.). The past two decades have witnessed an ever-growing interest in developing ABPP
probes for functional proteomics analysis.76–79 These probes greatly expanded our scope of the
“druggable” proteomes and led to the discovery of some potent and selective enzyme
inhibitors.77,80
1.6.1 ABPP Probes
Like mentioned earlier, a typical ABPP probe comprise a “warhead”, a tag, and a linker.
“Warheads” are usually small molecules with high affinity against the active site of an enzyme.
They can form covalent linkages with the amino acid residues (AAs) in the active site. Some
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Table 1. ABPP warhead groups on the left and the proteins that the
probes targeted.

representative “warheads’ are listed in Table 1.74 Most ABPP probes use electrophilic “warheads”
to covalently interact with nucleophilic AAs.
In the case when nucleophilic AAs are not available in the active site, photoaffinity groups
such as benzophenone, diazirine or azide can be incorporated into the probe. Upon UV irradiation,
these photoactivatable groups can form covalent bond with the AAs in their vicinity (Fig. 9. B.). 74
In ABPP probes, the tag can either be a fluorophore for visualization or a biotin for the
subsequent affinity enrichment.74 Special attention is given to the size of the tags because large
tags may interfere with the cell-permeability and cellular distribution of the ABPP probes.
Alternatively, “click” chemistry can be used to append a tag to the ABPP probes. “Click”
chemistry refers to the reaction between terminal alkyne and azide,81 two bioorthogonal functional
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B

Figure 9. A. Photocrosslinking groups on ABPP probes allow for probes to covalently
bind to their target enzymes. B. Schematic representation of benzophenone
photocrosslinking reaction to a metalloprotease

groups. These functional groups do not exist in the native biological system. However, the
presence of these groups will not interfere with the native cellular events. With the presence of
copper (I) catalyst, terminal alkyne and azide undergo intermolecular cycloaddition reaction to
form 1,4-disubstituted 1, 2, 3-triazole derivatives via the “click” chemistry.81 This reaction is
spontaneous and quantitative, and is very selective between alkyne and azide. 81 It demonstrates
broad functional group tolerance, and has been widely utilized to investigate various biological
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Figure 10. Schematic representation of comparative ABPP.

processes.82,83
The linker of an ABPP probe tethers the “warhead” and the tag together. The presence of
the linker reduces the potential steric hindrance from the tags. The linker length and composition
can be varied to sample the adequate proximity, favorable solubility and cell permeability. 74 Alkyl
linkers and polyethylene glycol (PEG)-based linkers are commonly used in ABPP probes. Linkers
can also provide selectivity/specificity for the ABPP probes. For example, in some protease
probes, the linker inherits the substrate peptide sequence that is specific for the protease target. 84
1.6.2 Comparative ABPP
In comparative ABPP, the functional states of enzymes are compared in normal and disease
states. It aims to discover enzyme activities closely associated with distinct physiological or
pathophysiological conditions.85,86 In the recent effort to uncover potential biomarkers for cancer
therapy, comparative ABPP was carried out for serine hydrolase (SH). 87,88 SHs are a large group
of proteases that play critical roles in the regulation of a myriad of cellular events such as
angiogenesis, hormone processing,89 and inflammatory response.90 More importantly, the
dysregulation of SH activity has been implicated in diseases such as cancers. 91 Despite the strong
physiological relevance of SHs, the cellular functions of many of them remained elusive. There is
a highly conserved catalytic triad including a serine, a histidine, and an aspartate in the active site
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Figure 11. ABPP of serine hydrolases (SH). A. The catalytic triad in the active site of SHs. B. The chemical
structures of ABPP probes for SHs. C. Schematic representation of the labeling protocol using the
fluorescent ABPP probe.

of SHs (Fig. 11. A.). Targeting the nucleophilic serine residue, a couple of fluorophosphonate
(FP)-based ABPP probes have been developed. 87 Both probes harbor the fluorophosphonate
“warhead” which will form covalent interaction with the active site serine (Fig. 11. B.). FP-biotin
carries the affinity tag, biotin, where FP-fluorescein bears a fluorophore (Fig. 11. C.). illustrates
the work flow of ABPP using FP-fluorescein.
SH activity was then profiled in a panel of breast cancer and melanoma cell lines using FPfluorescein.88 KIAA1363 was found to be significantly upregulated in the membrane proteomes
of the most invasive cancer cells. The ABPP result correlated well with the gene expression
pattern, suggesting that KIAA1363 could act as a biomarker for the invasiveness of cancer cells.
1.6.3 Competitive ABPP
ABPP technology has been adapted for inhibitor discovery, namely, competitive ABPP
(Fig. 12.). This type of study is normally performed in a parallel fashion in multi-well plates. To
each of the wells, same concentrations of target protein and identical buffer condition will be
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Figure 12. Competitive ABPP. In the top scheme the inhibitor prevents the ABPP probe from labeling the enzyme
leading to a dull signal. In the bottom scheme the inhibitor does not bind to the active site, allowing the ABPP
probe to bind more easily leading to a more intensely fluorescent band.

introduced. Subsequently, a different inhibitor candidate will be added to each well, followed by
the addition of an ABPP probe. There are two possible scenarios: on one hand, if the candidate
compound is indeed an inhibitor, it is going to block the active site of the enzyme to prevent the
ABPP from interacting with the target, leading to reduced or complete loss of labeling (Fig. 11.
top). Alternatively, the candidate compound may not be an inhibitor for the protein target. Then
the active site is still available for the normal labeling by the ABPP probe to occur (Fig. 11.
bottom). This method can be applied to cell lysates, so there is no need to recombinantly express
and purify the protein target. It does not require the use of substrate, which renders this approach
suitable for enzymes without known substrates. The competitive ABPP has been used for the
discovery of inhibitors for SHs, cysteine proteases, and lipases. 92
A study completed by Andrea Zuhl et al used competitive ABPP to identify selective
inhibitors for SHs.75,88 In this study flourophosphonate probes were used in a competitive assay to
determine if aza-β-lactams (ABLs) could be used as selective SH inhibitors. This idea that ABLs
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Figure 13. A. ABL127 a known inhibitor for Protein Phosphatase Methyltransferase 1 (PME1). Was
discovered from high throughput screening. B. ABL303 is a selective ABHD10 inhibitor that was
discovered using competitive ABPP.

might make for selective SH came from the discovery of ABL127 from high throughput screening.
(Fig. 13. A.) ABL127 is a selective inhibitor for Protein Phosphatase Methyltransferase 1 (PME1). In the study a mouse brain proteome was treated with both the flourophosphonate probes tagged
with biotin as well as prospective ABL inhibitors. This led Andrea Zuhl et al to ABL303, a
selective inhibitor of ABHD10 with nanomolar potency. (Fig. 13. B.) Looking at the differences
between ABL127 and ABL303 Andrea Zuhl et al concluded that minor alterations to ABLs could
lead to other selective inhibitors of SHs.
1.7 Goals of the current research
Short term goal:
1. To develop activity-based chemical probes for the profiling of MTase activity in their
native environment.
2. To apply the ABPP probes to the labeling and enrichment of recombinant MTases,
endogenous MTases in cell lysates.
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Long term goal:
Our group has a long-standing interest in generating creative chemical probes to study
enzymatic mechanisms, and developing novel therapeutics for diseases with unmet medical needs.
Recently, we have been using a highly integrative chemical biology approach to interrogate the
functional state of epigenetic modification enzymes in their native matrix. The current project is
in collaboration with Dr. Stanley Stevens at the University of South Florida. The project will
examine the impact of ethanol on the brain with specific focus on epigenetic regulation of
microglia through histone methylation and its influence on activation phenotype after ethanol
exposure. Although a growing body of data demonstrates the ability of ethanol to influence
changes in epigenetic modifications in various cell/tissue types, the ethanol-induced epigenetic
code and mechanisms underlying cell type-specific changes in this code are far from being
deciphered. The central hypothesis of the project is that alteration of the histone methylation code
could be a major regulatory event associated with various microglial activation phenotypes at
different stages of ethanol exposure. Our group is responsible for the synthesis and characterization
of ABPP probes targeting SAM-dependent MTases. Ethanol-induced activity changes of MTases
in microglia will be quantified by Dr. Stevens’ team using the ABPP probes in combination with
MS approaches. It is expected that changes in MTase activity through ethanol is important to define
a complete mechanistic network involved in microglia activation mediated by histone methylation.
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2. Experimental Section
2.1 Specific Aims
2.1.1 Aim 1: Design and synthesis of SAM-based chemical probes for MTase profiling.
The human proteome encoded more than 200 MTases. Despite the intense pursuit of
MTases as potential therapeutic targets, the endogenous substrates and biological functions of
many MTases remain elusive. The need for innovative chemical probes to evaluate MTase activity
in the native biological matrix becomes apparent. In this aim, we will develop an ABPP probe to
enable the subsequent profiling of MTase activity in native biological samples. This probe (probe
1, Fig 14.) is a structural analog of SAM with several major components: 1) a methylated nitrogen
“warhead” mimics the positively charged sulfur in SAM; 2) a photocrosslinkable azido group for
the covalent modification of the target enzyme; and 3) a biotin tag for the subsequent affinity
capture by streptavidin beads.
SAM is a universal methyl donor for MTases. The SAM analog, probe 1, should be readily
recognized by the MTase family members. To enhance the small molecule-protein interaction, a

Figure 14. Chemical structure of SAM and probe 1. In red we see the modified SAM warhead
group. Instead of a sulfur group in SAM we instead see an amine group. This makes the methyl a
poor leaving group and should allow the probe to spend more time in the binding pocket. In blue we
see the azide photocrosslinking group. When exposed to a specific wavelength of light in close
proximity to a protein it will covalently bond the probe to the protein. The final group is green, the
biotin tag. The biotin tag will allow the probe to bind to streptavidin beads, and be separated from
cell supernatant.
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photoactivatable azido group is introduced at the 8-position of the adenine ring. Upon photo
irradiation, it is expected that this group will form an irreversible, covalent adduct with the AAs
in its vicinity. Azido group is chosen as the photoaffinity group because of its small size and good
quantum yield. And there is ample literature precedent on the installation of azido groups on
nucleobases. Careful inspection of the crystal structures of several MTases suggests that the
exocyclic amino group at the C6 position of the adenine ring is solvent accessible and can easily
accommodate a biotin tag. The biotin tag is tethered to the adenine ring through a hexadiamine
linker to reduce the potential steric hindrance.
Figure 15 illustrates the synthetic plan for probe 1. Commercially available 8-bromoinosine
can be protected using acetic anhydride and DMAP in anhydrous CH 2Cl2 to generate 2', 3', 5'-Otriacetyl-8-bromoinosine. Subsequently, the azido group can be readily installed at 8-position with
sodium azide in DMF furnishing intermediate 3. Mono-N-Boc-1,6-diaminohexane will be coupled
to the 6-position with PyBOP in the presence of DIPEA to generate N6-substituted adenosine 4.
The deprotection of the N-Boc group in intermediate 4 will be accomplished with trifluoroacetic
acid (TFA) yielding intermediate 5. Biotin can then be coupled to the primary amino group using
EDCI/DMAP to form the N6-biotinylate-8-azido-adenosine 6. Finally, the 5᾿-hydroxy group will
be selectively deprotected in ammonia in methanol at -40°C to afford the photocrosslinkable
adenosine derivative probe 2.
The later stage of the synthesis will focus on the installation of the “warhead” onto the 5᾿position of probe 2 (Fig. 15). The 5’-hydroxy group can be activated with methanesulfonyl
chloride to obtain mesylate 7. Intermediate 7 can then be treated with methylamine, during which
the installation of the methylamino functionality and the deprotection of 2’ and 3’-hydroxy groups
will be accomplished simultaneously. The subsequent reductive amination between intermediate
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Figure 15. Synthetic scheme 1

8 and tert-butyl (S)-2-[N-(tert-butoxycarbonyl) amino]-4-oxobutanoate in the presence of
NaBH3CN and acetic acid will lead to the formation of intermediate 9. Finally, the global
deprotection with 4N HCl in dioxane will provide the desired photocrosslinkable SAM analog,
probe 1.
Most of the reactions listed above have literature precedent, and some of them have been
tested out on small scales in Dr. Cen’s lab to confirm feasibility. All the new compounds
synthesized will be fully characterized by 1H NMR, 13C NMR and HRMS.
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2.1.2 Aim 2: Biochemical characterization of SAM-based chemical probes.
2.1.2.1 Aim 2.1 Establishment and optimization of recombinant MTase labeling and
enrichment using SAM-based chemical probes.
Photoaffinity labeling and the subsequent affinity enrichment of recombinant MTase with
the synthetic probes serves as the model study. Recombinant protein has the advantage of being
ample in amount and free of background noise. Important labeling parameters can be easily
optimized to enable accurate profiling of active enzymes. Technical details will be fine-tuned to
achieve fast, selective, and efficient labeling. The optimized protocols will then be applied to
proteome labeling using cell lysates.
Euchromatin histone lysine methyltransferase 1 (EHMT1) belongs to the lysine
methyltransferase subfamily. Extensive studies on EHMT1 have revealed its role in epigenetic
silencing of gene transcription and DNA repair. It has also been closely associated with genetic
Alzhemer’s disease and various cancers. The plasmid of human EHMT1 is commercially available
from Addgene. We plan to purchase the plasmid and recombinantly express and purify the protein
using a published protocol. The identity of the protein will be confirmed by tryptic digestion
followed by LC-MS/MS analysis performed at the Vermont Biomedical Research Network
Proteomics Facility.
The purified protein will then be subjected to the photoaffinity labeling and affinity capture
process. EHMT1 will be incubated with the ABPP probe, followed by UV irradiation to affect the
covalent conjugation. Subsequently, streptavidin beads will be introduced to the sample to capture
the biotinylated EHMT1. Ultimately, EHMT1 will be eluted off the beads and analyzed by western
blot. Several parameters such as irradiation time, probe dosage, and elution conditions will be
further optimized. It is expected that probe 1, a close analog of SAM, can efficiently label EHMT1.
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One of the major challenges in photoaffinity labeling is the non-specific labeling, which
may create false positive results. To rule out the possibility of off-target effect, competition
labeling experiments will also be performed. The introduction of excess amount of a known
EHMT1 inhibitor should out-compete the labeling of EHMT1 by probe 1, confirming the on-target
effect of the ABPP probe.
2.1.2.2 Aim 2.2 Cell lysate labeling using ABPP probes.
Probe 1 will be applied to the labeling of MTases in cell lysate. The identities of the labeled
proteins can be further verified by either western blot or Mass Spectrometry (MS). This strategy
has the advantage of enriching for the active enzymes independently of protein abundance,
allowing the capture of dynamic enzyme activity changes in response to environmental and cellular
stimuli.
2.2 Methods
2.2.1 Synthesis
All reagents and solvents were purchased from Fisher Scientific (Somerville, NJ) or SigmaAldrich (St. Louis, MO) and used without additional purification.

Scheme 1. the protection of the 2, 3, and 5 positions of the ribose sugar
ring on 8-bromoinosine.

In a 100 mL 24/40 flame dried round bottom flask and a solution of 8-bromoinosine (1 g, 2.881
mmol) and DMAP (35.2 mg, 0.288 mmol) in dry dichloromethane (10 mL) was cooled at 0°C for
5-7 mins. To the cooled reaction mixture acetic anhydride (2.72 mL, 28.808 mmol) was slowly
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added. After 2 hours of stirring at 0°C, while ice was continuously added, the mixture was taken
off of ice and stirred at room temperature overnight. The next morning the reaction mixture was
quenched with ice water mixture and the ice was allowed to melt before extraction. The reaction
mixture was washed with DCM (3 x 10 mL) before the organic layer was pooled and washed with
saturated solution of sodium bicarbonate (3 x 10 mL) followed by brine. The dichloromethane
layer was dried over anhydrous sodium sulfate and concentrated to a pale-yellow oil and subjected
to flash column chromatography (5% MeOH/DCM).6 68.7% isolated yield. 1H NMR (400 MHz,
CDCl3) δ 12.43 (s, 1H), 8.09 (s, 1H), 6.23 (t, J = 5.2 Hz, 1H), 6.10 (dd, J = 4.6, 2.3 Hz, 1H), 5.78
(t, J = 6.0 Hz, 1H), 4.60 – 4.03 (m, 2H), 2.16 (s, 1H), 2.11 (s, 1H), 2.07 (s, 1H). 13C NMR Mass
Spec HRMS (ESI) C16H17BrN4O8 Calc. 413.2322, found 414.1113.

Scheme 2. The addition of the photo crosslinking azide group to
intermediate 1.

Add NaN3 (403.1 mg, 6.201 mmol) to a solution of 2’,3’,5’-O-triacetyl-8-bromoinosine (733.6
mg, 1.550 mmol) in 3 mL of anhydrous DMF in a 50 mL flame dried 24/40 round bottom flask.
The reaction was stirred at 80°C while being monitored by TLC until the consumption of starting
material. The reaction was cooled down to room temp and the solvent was removed under reduced
pressure. Water (5 mL) was added to the reaction mixture and the product was extracted with
dichloromethane (3 times). The combined organic layer was washed with sat. NaHCO 3, water and
brine and dried over Na2SO4 before being filtered and concentrated down.66 60.2% isolated yield.
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1H NMR (400 MHz, CDCl3) δ 12.43 (s, 0H), 8.09 (s, 0H), 6.23 (t, J = 5.2 Hz, 0H), 6.10 (dd, J =
4.6, 2.3 Hz, 1H), 5.78 (t, J = 6.0 Hz, 1H), 4.60 – 4.03 (m, 2H), 2.16 (s, 1H), 2.11 (s, 1H), 2.07 (s,
1H). 13C NMR (101 MHz, CDCl3) δ 206.82, 170.41, 169.48, 169.35, 157.65, 148.77, 145.08,
144.09, 123.20, 85.76, 79.89, 77.32, 77.21, 77.00, 76.69, 71.97, 70.32, 63.02, 30.88, 20.65, 20.47,
20.38. NMR Mass Spec HRMS (ESI) C16H17N7O8 Calc. 458.1032, found 458.1012.

Scheme 3. A PyBOP coupling reaction is completed to add the Boc protected linker region.

N, N-Diisopropylethylamine (23 µL, 0.134 mmol) was added to a solution of 2’,3’,5’-Otriacetyl-8-azidoinosine (29.1 mg, 0.067 mmol) and PyBOP (2.341 g, 4.5 mmol) in 2.0 mL HPLC
grade acetonitrile and stirred until the solution turned clear, this took 15 minutes. Mono-N-Boc1,6-hexandiamine (6.0 mmol) was added drop wise and the reaction was stirred overnight at room
temperature. The reaction was diluted with Et2O and washed twice each with 1 M acetic acid,
saturated NaHCO3, and brine. The organic layer was dried over Na2SO4 and concentrated. The
crude residue was purified by silica gel column chromatography, using a mobile phase that is 4:1
to 1:2 Hexane/EtOAc.6 55.0% isolated yield. 1H NMR (400 MHz, CDCl3) δ 8.27 (s, 1H), 6.18 –
6.11 (m, 1H), 5.98 (d, J = 4.5 Hz, 1H), 5.81 (t, J = 5.5 Hz, 1H), 4.54 – 4.43 (m, 2H), 4.37 – 4.25
(m, 2H), 3.64 (s, 2H), 3.11 (q, J = 6.8 Hz, 3H), 2.13 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 1.50 (q, J
= 7.1 Hz, 2H), 1.45 (s, 4H), 1.38 (q, J = 8.6, 7.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 206.78,
170.50, 169.49, 169.39, 155.99, 144.20, 85.43, 79.83, 77.32, 77.21, 77.01, 76.69, 72.00, 70.47,
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63.05, 53.39, 30.87, 30.02, 29.78, 28.42, 26.48, 26.44, 20.65, 20.49, 20.41.. Mass Spec HRMS
(ESI) C15H17N7O6Na+ Calc. 414.1138, found 414.1113.

Scheme 4. Boc deprotection of intermediate 3.

A

solution

of

2',3',5'-Tri-O-acetyl-8-azido-6-(N6-tert-butoxycarboyl-6-amino-

1002D`hexylamino)-purine riboside (451.2 mg, 0.712 mmol) in 9:1 dry DCM:TFA (8 mL) was
stirred at room temperature for 4 hours. The reaction was followed by TLC for complete
deprotection of N-Boc group and formation of the desired product. The TFA was removed by
rotovap. Next 100 µL of TEA was added along with additional DCM and water. The aqueous layer
was rinsed and extracted with DCM 3×. The DCM was dried over anhydrous sodium sulfate and
concentrated to pale yellow solid.6 79.5% isolated yield. 1H NMR (400 MHz, CDCl3) δ 8.22 (s,
1H), 6.15 (t, J = 5.3 Hz, 1H), 5.96 (d, J = 4.7 Hz, 1H), 5.80 (t, J = 5.6 Hz, 1H), 4.46 (dd, J = 10.9,
2.6 Hz, 1H), 4.35 – 4.23 (m, 2H), 3.59 (s, 2H), 2.91 (t, J = 7.7 Hz, 2H), 2.11 (s, 3H), 2.06 (s, 3H),
2.03 (s, 3H), 1.63 (p, J = 7.1 Hz, 5H), 1.38 (p, J = 3.4 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ
206.94, 170.61, 169.58, 169.50, 162.94, 162.58, 162.23, 153.18, 152.13, 144.14, 120.76, 117.86,
117.76, 114.96, 112.07, 85.41, 79.79, 77.34, 77.23, 77.03, 76.71, 71.99, 70.47, 63.06, 40.77, 39.81,
30.86, 29.67, 29.41, 27.28, 26.06, 25.86, 20.62, 20.48, 20.39. HRMS (ESI) C26H40N9O7Na+
Calc. 612.2870, found 612.2901.
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Scheme 5. EDCI coupling of the biotin tag to the linker region of intermediate 4.

To a solution of biotin (6.5 mg, 0.027 mmol), EDCI·HCl (5.1 mg, 0.027 mmol), and DMAP
(4.9 mg, 0.040 mmol) in dry DMF (2 mL), a solution of crude 2',3',5'-Tri-O-acetyl-8-azido-6-(N6tert-butoxycarboyl-6-amino-1-hexylamino)-purine riboside (14.3 mg, 0.027 mmol) in dry DCM
(2 mL) was slowly added; the solution was stirred at room temperature for 8 hours. Water (8 mL)
was added the reaction and the aqueous layer was extracted 3x with DCM. The organic layers were
pooled together and washed with brine solution (1 × 10 mL). The DCM extract was dried over
anhydrous sodium sulfate and concentrated to a pale yellow solid and subjected to reversed-phase
column chromatography (30-100% acetonitrile in H2O) to give 8 (256 mg, 72%) after freezedrying.6 62.0% isolated yield. 1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 3.4 Hz, 1H), 6.49 (d, J
= 33.9 Hz, 1H), 6.28 – 6.12 (m, 2H), 5.95 (d, J = 4.4 Hz, 1H), 5.92 – 5.73 (m, 3H), 4.47 (dd, J =
8.1, 5.4 Hz, 2H), 4.29 (h, J = 5.9 Hz, 3H), 3.52 (d, J = 57.4 Hz, 2H), 3.22 – 3.05 (m, 3H), 2.87 (dd,
J = 12.7, 4.6 Hz, 1H), 2.69 (d, J = 12.8 Hz, 1H), 2.17 (t, J = 7.4 Hz, 2H), 2.11 (s, 3H), 2.05 (dd, J
= 11.5, 2.4 Hz, 7H), 1.78 – 1.57 (m, 7H), 1.49 (t, J = 7.0 Hz, 1H), 1.45 (s, 0H).13C NMR (101
MHz, CDCl3) δ 173.23, 170.63, 169.63, 169.55, 164.19, 153.45, 152.55, 144.11, 117.89, 85.56,
79.91, 77.48, 77.36, 77.16, 76.84, 72.12, 70.58, 63.18, 61.98, 60.27, 55.80, 50.72, 40.72, 39.51,
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36.03, 29.73, 29.57, 28.24, 28.15, 26.69, 26.58, 25.73, 20.77, 20.60, 20.54. HRMS (ESI)
C33H47N11O9Na+ Calc. 796.31, found 782.3022.

Scheme 6. Our goal was to selectively deprotect the 5-position acetyl group, but we realized that this would
not be possible when we were left with the monoprotected product.

An ammonia solution was slowly added to a solution of 2',3',5'-Tri-O-acetyl-8-azido-6-(N6biotinyl-6-amino-1-hexylamino)-purine riboside 3mg (0.067 mmol) in MeOH (1.5 mL) while
being stirred at -40˚C in a ice/salt water bath for 2 hours. The reaction mixture was diluted with
MeOH and concentrated immediately under vacuum to give a foamy solid which was purified by
HPLC chromatography (20-80% acetonitrile in H 2O) followed by freeze-drying to give 1 (57 mg,
61%) along with small amount of the monoprotected derivative. The goal of synthesizing the
monodeprotected product (probe 2) was unsuccessful with this method, the product that was
formed was the monoprotected compound (probe 3).6 46.6% isolated yield. 1H NMR (400 MHz,
MeOD) δ 8.16 (s, 1H), 5.84 (d, J = 4.9 Hz, 1H), 5.08 (t, J = 5.2 Hz, 1H), 4.55 (t, J = 5.3 Hz, 1H),
4.49 – 4.40 (m, 2H), 4.29 (td, J = 7.0, 4.8 Hz, 2H), 4.18 – 4.10 (m, 1H), 3.59 (d, J = 15.8 Hz, 2H),
3.24 – 3.13 (m, 3H), 2.91 (dd, J = 12.8, 5.0 Hz, 1H), 2.71 (s, 1H), 2.01 (s, 3H), 1.80 – 1.37 (m,
16H). 13C NMR HRMS (ESI) C29H43N11O7Na+ Calc. 712.77, found 698.2789.
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Scheme 7. the protection of the 2 and 3 position with 2,2dimethylpropane.

In a flame dried round bottom flask add 8-bromoinosine (100 mg, 0.289 mmole) was dissolved
in a 5 mL of a 4:1 v/v acetone:2,2-dimethoxypropane solution. Next p-TsOH (55.0 mg, 0.289
mmole) was added to the reaction mixture and the reaction was stirred at room temperature
overnight. The reaction goes from a cloudy off white to a cloudy red orange. The solution was
stirred overnight at room temperature before solid NaHCO 3 (24.3mg, 0.289 mmol) was added
slowly in small portions, followed by saturated NaHCO3 (932.3 µL). The reaction mixture was
stirred for 1 hour before the salts were filtered off. After adding the sodium bicarbonate, the
reaction changes from the cloudy red/orange to a cloud faint off white/yellow. The filtrate was
concentrated down and purified by column chromatography on silica gel eluting with 10%
MeOH/DCM (v/v).10 83.5% isolated yield. 1H NMR (600 MHz, CDCl3) δ 12.98 (s, 2H), 8.37 (s,
1H), 6.09 (d, J = 4.7 Hz, 2H), 5.25 (t, J = 5.4 Hz, 2H), 5.06 (dd, J = 5.8, 2.0 Hz, 2H), 4.48 (dt, J =
4.0, 2.1 Hz, 2H), 3.93 (ddd, J = 12.8, 4.1, 2.0 Hz, 2H), 3.79 (d, J = 12.5 Hz, 2H), 1.66 (s, 5H), 1.38
(s, 5H). 13C NMR (101 MHz, CDCl3) δ 157.75, 149.39, 146.55, 126.90, 126.50, 114.87, 93.74,
86.30, 83.32, 81.72, 77.79, 77.68, 77.48, 77.16, 63.47, 30.13, 28.04, 25.88. HRMS (ESI)
C13H15BrN4O5Na+ Calc. 410.00, found 452.0362.
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Scheme 8. the protection of the 5-position hydroxyl group with an
acetyl group.

In a 50 mL 24/40 flame dried round bottom flask and a solution of 8-bromoinosine (50.0 mg,
7.202 mmol) and DMAP (3.2 mg, 0.0259 mmol) in dry dichloromethane (2 mL) was cooled at
0°C for 5-7 minutes. TEA (27.1 uL, 0.1943 mmole) was added to the cooled reaction mixture
followed by acetic anhydride (13.4 µL, 0.1425 mmol). After 2 hours of stirring at 0°C, with ice
continuously added, the mixture was taken off of ice and stirred at room temperature overnight.
The next morning the reaction mixture was quenched with an ice water mixture, and the ice was
given time to melt before extraction. The reaction mixture was washed with 10 mL of DCM 3
times before the organic layer was pooled and washed with saturated solution of sodium
bicarbonate followed by brine. The dichloromethane layer was dried over anhydrous sodium
sulfate and concentrated then subjected to flash column chromatography (5% MeOH/DCM). 6
99.4% isolated yield. 1H NMR (400 MHz, CDCl3) δ 13.10 (s, 1H), 8.35 (s, 1H), 6.22 (d, J = 1.9
Hz, 1H), 5.55 (d, J = 1.9 Hz, 1H), 5.12 (dd, J = 6.4, 4.2 Hz, 1H), 4.44 – 4.29 (m, 2H), 4.19 (dd, J
= 11.6, 7.2 Hz, 1H), 2.04 (s, 3H), 1.62 (s, 3H), 1.40 (s, 3H). 13C NMR (101 MHz, CDCl3) δ
170.53, 157.82, 149.56, 145.90, 126.58, 125.59, 114.90, 91.19, 85.32, 83.70, 81.70, 77.36, 77.24,
77.04, 76.72, 63.82, 29.69, 27.21, 25.43, 20.77. HRMS (ESI) C13H15N7O5Na+ Calc. 451.01,
found 453.0163.
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Scheme 9. The azide photocrosslinking group is added to
intermediate 11.

To a solution of 2',3'-O-isopropylidenel-5’-O-acetyl-8-bromoinosine (55.4 mg, 0.1294 mmol)
in 6 mL of anhydrous DMF was added NaN3 (33.7 mg, 0.5177 mmol) in a 50 mL flame dried
24/40 round bottom flask. The reaction was stirred at 80°C while being monitored by TLC until
the consumption of starting material. The reaction was cooled down to room temp and the solvent
was removed under reduced pressure. Water (5 mL) was added to the reaction mixture and the
product was extracted with dichloromethane (3 times). The combined organic layer was washed
with sat. NaHCO3, water and brine and dried over Na2SO4 before being filtered and concentrated
down.66 82.9% isolated yield. 1H NMR (400 MHz, CDCl3) δ 13.36 (s, 1H), 8.26 (s, 1H), 6.01 (d,
J = 2.0 Hz, 1H), 5.39 (dd, J = 6.4, 2.0 Hz, 1H), 5.01 (dd, J = 6.6, 3.5 Hz, 1H), 4.37 – 4.26 (m, 2H),
4.15 (dt, J = 10.5, 4.6 Hz, 1H), 2.01 (s, 3H), 1.57 (s, 3H), 1.35 (s, 3H). 13C NMR (101 MHz,
CDCl3) δ 170.55, 162.67, 158.02, 148.57, 145.00, 144.94, 123.04, 114.85, 88.52, 85.00, 83.55,
81.63, 77.48, 77.36, 77.16, 76.84, 63.94, 36.55, 31.49, 27.20, 25.43, 20.77. C15H17N7O6Na+
Calc. 414.10, found 414.0931.
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Scheme 10. The addition of the linker region to intermediate 12.

N, N-Diisopropylethylamine (22.5 µL, 0.1293 mmol) was added to a solution of 2',3'-Oisopropylidenel-5’-O-acetyl-8-azidoinosine (25.3 mg, 0.0646 mmol) and PyBOP (50.5 mg, 0.0970
mmol) in 2.0 mL sure sealed dry HPLC grade acetonitrile and stirred until the solution turned clear
(15 min). Mono-N-Boc-1,6-hexandiamine (29.0 µL, 0.1293 mmol) was added drop wise and the
reaction was stirred overnight at room temperature. The reaction was quenched with water and
washed 3x with EtOAc. The organic layer was pooled together and washed once with brine. The
organic layer was dried over Na2SO4 and concentrated. The crude residue was purified by column
chromatography (silica gel, 7% MeOH in DCM).9 81.9% isolated yield. 1H NMR (400 MHz,
CDCl3) δ 8.24 (s, 1H), 6.00 (d, J = 1.9 Hz, 1H), 5.53 (dd, J = 6.4, 2.0 Hz, 2H), 5.11 (dd, J = 6.5,
3.2 Hz, 1H), 4.55 (s, 1H), 4.38 – 4.27 (m, 2H), 4.21 – 4.11 (m, 1H), 3.64 – 3.57 (m, 2H), 3.09 (q,
J = 6.7 Hz, 2H), 2.01 (s, 3H), 1.66 (p, J = 7.1 Hz, 2H), 1.42 (s, 11H), 1.37 (s, 4H). 13C NMR (101
MHz, CDCl3) δ 170.68, 156.12, 153.35, 152.31, 152.06, 151.66, 149.94, 148.86, 144.35, 142.90,
119.97, 118.53, 118.02, 114.54, 114.45, 110.15, 88.48, 88.41, 85.26, 83.53, 83.46, 82.11, 82.01,
79.15, 77.48, 77.36, 77.16, 76.84, 64.26, 64.16, 47.18, 47.13, 40.56, 30.12, 29.87, 28.54, 27.29,
26.60, 26.55, 26.50, 26.45, 26.41, 25.60, 25.57, 20.86. HRMS (ESI) C26H39N9O7Na+ Calc.
589.30, found 590.3062.
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Scheme 11. The selective deprotection of the Boc group on the linker of intermediate 13.

A solution of 2',3'-O-isopropylidenel-5’-O-acetyl-N6-N-Boc-hexandiamine-8-azidoinosin
(79.1 mg, 0.1342 mmol) in 4:1 dry DCM: TFA (2:0.5 mL) was stirred at 0°C in an ice/water bath
for 2 hours. The reaction was followed by TLC for complete deprotection of N-Boc group and
formation of the desired product. The TFA was removed by rotovaping. Next 100 µL of TEA was
added along with additional DCM and water. The aqueous layer was rinsed and extracted with
DCM 3 times. The DCM was dried over anhydrous sodium sulfate and concentrated to pale yellow
solid). (CH2Cl2/CH3OH, 90/10, v/v).93 99.7% isolated yield. 1H NMR (400 MHz, MeOD) δ 8.16
(s, 1H), 6.00 (d, J = 1.9 Hz, 1H), 5.57 (dd, J = 6.3, 1.9 Hz, 1H), 5.12 (dd, J = 6.4, 3.5 Hz, 1H), 4.36
– 4.15 (m, 4H), 3.57 (s, 2H), 3.36 (s, 1H), 3.32 (p, J = 1.7 Hz, 1H), 2.93 (t, J = 7.7 Hz, 2H), 1.98
(s, 3H), 1.68 (ddt, J = 14.8, 11.0, 6.7 Hz, 5H), 1.57 (s, 3H), 1.54 – 1.44 (m, 5H), 1.37 (s, 3H). 13C
NMR (101 MHz, MeOD) δ 172.30, 154.43, 152.89, 149.76, 145.87, 115.46, 89.75, 86.34, 84.55,
83.14, 65.01, 49.85, 49.64, 49.43, 49.28, 49.21, 49.07, 49.00, 48.79, 48.57, 48.36, 40.64, 28.48,
27.41, 27.36, 27.14, 25.52. HRMS (ESI) C21H31N9O5Na+ Calc. 489.24, found 490.2504.
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Scheme 12. The addition of the biotin tag to intermediate 14.

To a solution of biotin (21.5 mg, 0.0879 mmol), EDCI·HCl (16.8 mg, 0.0879 mmol), and
DMAP (16.0 mg, 0.1310 mmol) in dry DMF (2 mL), a solution of 22',3'-O-isopropylidenel-5’-Oacetyl-8-azido-6-(6-aminohexylamino)-purine riboside (43.0 mg, 0.0879 mmol) in dry DCM (4
mL) was slowly added; the solution was stirred at room temperature for 8 hours. Water (8 mL)
was added to the reaction and the aqueous layer was extracted 3 times with DCM. The organic
layers were pooled together and washed with 10 mL brine solution on time. The DCM extract was
dried over anhydrous sodium sulfate and concentrated to a pale yellow solid and columned with
silica in a mobile phase of (CH2Cl2/CH3OH, 90/10, v/v).6 60.6% isolated yield. 1H NMR (400
MHz, CDCl3) δ 8.23 (s, 1H), 6.45 (s, 1H), 6.22 (t, J = 5.7 Hz, 1H), 6.00 (d, J = 1.8 Hz, 1H), 5.79
(s, 1H), 5.53 (dd, J = 6.3, 1.9 Hz, 1H), 5.16 – 5.07 (m, 1H), 4.49 (dd, J = 7.8, 4.9 Hz, 1H), 4.37 –
4.28 (m, 3H), 4.16 (dt, J = 10.3, 4.7 Hz, 1H), 3.60 (s, 2H), 3.30 – 3.11 (m, 3H), 2.71 (d, J = 12.7
Hz, 1H), 2.18 (t, J = 7.3 Hz, 2H), 1.68 (ddp, J = 18.3, 13.3, 6.6 Hz, 7H), 1.58 (s, 4H), 1.50 (t, J =
7.2 Hz, 2H), 1.43 (q, J = 7.4 Hz, 5H), 1.38 (s, 5H), 1.24 (s, 5H). 13C NMR (101 MHz, CDCl3) δ
173.15, 170.59, 164.06, 153.00, 144.29, 117.82, 114.49, 88.39, 85.14, 83.33, 81.87, 77.36, 77.24,
77.04, 76.72, 64.03, 61.87, 60.13, 55.70, 40.66, 39.38, 37.09, 36.47, 35.90, 32.74, 31.92, 31.43,
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30.03, 29.69, 29.57, 29.44, 29.35, 28.09, 28.02, 27.18, 27.08, 26.55, 26.44, 25.63, 25.46, 22.68,
20.77, 19.73, 14.11. HRMS (ESI) C31H45N11O7SNa+ Calc. 715.83, found 716.3268.
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Scheme 13. The selective deprotection of the 5-position acetyl group on intermediate 15 was completed giving us
Probe 4.

To a round bottom flask of 2',3'-O-isopropylidenel-5’-O-acetyl-8-azido-6-(N6-biotinyl-6amino-1-hexylamino)-purine riboside (23.1 mg, 0.0323 mmol) 1 mL of the ammonia 7 N in
Methanol solution was slowly added. The argon line was removed and the reaction was monitored
every 30 minutes while stirring at -20˚C (ice/NaCl bath) monitoring for the consumption of starting
material. The reaction mixture was diluted with MeOH and concentrated immediately under
vacuum to give a foamy solid which was purified by silica column (DCM/MeOH, 90/10, (v/v)). 6
79.9% isolated yield. 1H NMR (400 MHz, MeOD) δ 8.18 (s, 1H), 5.98 (d, J = 3.4 Hz, 1H), 5.44
(dd, J = 6.1, 3.4 Hz, 1H), 5.09 (dd, J = 6.1, 2.7 Hz, 1H), 4.51 (ddd, J = 7.9, 5.0, 1.0 Hz, 1H), 4.33
(tt, J = 4.8, 2.0 Hz, 2H), 3.82 (dd, J = 12.2, 4.0 Hz, 1H), 3.72 (dd, J = 12.2, 4.8 Hz, 1H), 3.63 (d, J
= 12.0 Hz, 2H), 3.22 (ddd, J = 9.2, 5.6, 2.5 Hz, 3H), 2.94 (dd, J = 12.7, 5.0 Hz, 1H), 2.73 (d, J =
12.7 Hz, 1H), 2.23 (t, J = 7.3 Hz, 2H), 1.73 (dddd, J = 20.6, 17.6, 9.0, 6.7 Hz, 6H), 1.64 (s, 3H),
1.61 – 1.43 (m, 9H), 1.42 (s, 3H). 13C NMR (101 MHz, MeOD) δ 174.55, 151.44, 144.47, 113.87,
89.63, 86.73, 82.80, 81.53, 62.25, 61.98, 60.21, 55.60, 48.23, 48.02, 47.80, 47.59, 47.38, 47.17,
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46.95, 39.61, 38.89, 35.41, 28.96, 28.36, 28.10, 26.32, 26.28, 26.21, 25.52, 24.17. HRMS (ESI)
C29H43N11O6Na+ Calc. 673.31, found 696.2992.

Scheme 14. The addition of a good leaving group, a Mesylate, is added to the 5-position of the ribose
ring of probe 4.

Triethylamine (6 µL, 0.0431 mmol) and methanesulfonyl chloride (1.7 µL, 0.0216 mmol) were
added to a solution of the N6 substituted adenosine (12.1 mg, 0.0180 mmole) in 1 mL DCM. The
reaction was stirred for 1 hour and then quenched with saturated NH 4Cl. The layers were separated
and the organic layer. The aqueous layer was extracted twice with DCM, then the organic layers
were pooled together, washed with brine, dried over Na2SO4 and concentrated. NMR crude if TEA
is gone and looks right push forward. (Mohamed Ramadan, 2014) 35.6% isolated yield. 1H NMR
(400 MHz MeOD) δ 8.0736 (s, 1H), 5.8710 (d, J=2.7919 Hz, 1H), 5.3364 (dd, J=3.6294, 5.5837
Hz, 1H), 4.9959 (d, J=5.8629 Hz, 1H), 4.9404 (dd, J=6.1412, 8.9339 Hz, 1H), 4.4252 (t, J=5.3045
Hz, 2H), 4.2404 (d, J=3.9086 Hz, 2H), 3.7387 (tdd, J=3.6294, 12.005, 29.3145 Hz, 3H), 3.2952
(d, J=15.3552 Hz, 3H), 2.9169 (td, J=4.7462, 12.5634 Hz, 2H), 2.6363 (d, J=9.7715 Hz, 2H),
2.1501 (t, J=7.2588 Hz, 3H), 1.711 (ddt, J=7.2588, 13.4009, 34.3399 Hz, 8H), 1.5597 (dt,
J=8.9339, 30.4313, 9H), 1.4057 (quintet, J=7.2588, 13H), 1.2482 (s, 1H). C30H45N11O8S2Na+
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Scheme 15. The mesyl group on the 5-position of the ribose ring is substituted for a methylamine group.

The N6 substituted mesylate (1.0 mmol) was brought up in 3mL of methylamine (50 mmol)
and stirred for 3 days. The volatiles were evaporated off under high vacuum with gentle heating
using a distillation apparatus. Upon addition of brine to the resulting material, the product was
extracted with EtOAc, washed with brine, dried over Na2SO4 and concentrated. The crude residue
was purified by column chromatography (silica gel, 9:1 to 7:3 DCM/MeOH). 9 26.6% isolated
yield. 1H NMR 1H NMR (400 MeOD) δ 8.1208 (s, 1H), 6.2779 (s, 1H), 5.5198 (s, 1H), 4.9868
(d, J=5.7904 Hz, 1H), 4.6811 (s, 1H), 4.6169 (d, J=5.6647 Hz, 1H), 4.5092 (dd, J=4.7425, 7.9042
Hz, 1H),4.3254 (dd, J=4.4791, 7.9042 Hz, 1H), 3.5883 (t, J=6.9821 Hz, 2H), 3.5210 (quintet,
J=1.5808 Hz, 1H), 3.4790 (dd, J=3.0300, 13.8324 Hz, 1H), 3.3796 (s, 1H), 3.2860 (d, J=1.5808
Hz, 1H), 3.2235 (td, J=6.7186, 2.1078 Hz, 4H), 3.1718 (quintet, J=1.5808 Hz, 1H), 2.9514 (dd,
J=4.8743, 12.6468 Hz, 2H), 2.7317 (d, J=12.7785 Hz, 2H), 2.2331 (t, J=7.3773 Hz, 2H), 1.7424
(dd, J=7.1138, 13.8324 Hz, 2H), 1.6699 (d, J=2.2395 Hz, 1H), 1.6450 (dd, J=7.6408, 21.3415 Hz,
3H), 1.5454 (s, 5H), 1.5107 (dt, J=7.3773, 14.0959 Hz, 9H), 1.3587 (s, 4H), 1.3239 (s, 2H).
C30H46N12O5SNa+
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Scheme 16. The addition of the protected warhead to intermediate 8 was preforming using a reductive animation
reaction.

NaBH3CN (0.048 g, 0.771 mmol) and glacial acetic acid (29.4 µL, 0.514 mmol) were added
to a solution of the N6-substituted Nmethylamine adenosine (0.566 mmol) and tert-butyl (S)-2[N-(tertbutoxycarbonyl) amino]-4-oxobutanoate (0.1405 g, 0.514 mmol) in 2 mL dry MeOH. The
reaction mixture was stirred overnight. After diluting the reaction with EtOAc and saturated
NaHCO3, the organic layer was washed with saturated NaHCO3, dried over Na2SO4 and
concentrated. The crude residue was purified by column chromatography (silica gel, 8:4:2:1 Pet
Ether/EtOAc/CH2Cl2/MeOH).9 22.9% isolated yield (400 MHz MeOD) δ 8.1022 (s, 1H), 6.2454
(d, J=1.7726 Hz, 1H), 5.7123 (dd, J=1.8386, 6.3038 Hz, 1H), 5.1860 (dd, J=3.6772, 6.2382 Hz,
1H), 4.5929 (s, 1H), 4.2772 (dd, J=4.0564, 5.2856 Hz, 3H), 3.6675 (s, 1H), 3.1637 (s, 1H), 2.8927
(s, 1H), 2.6413 (d, 3.2417 Hz, 1H), 2.2416 (t, J=7.4095 Hz, 1H), 2.0360 (s, 1H), 2.0217 (s, 1H),
1.6255 (d, J=8.4901 Hz, 6H), 1.5500 (dd, J=2.4698, 6.3290 Hz, 7H), 1.5065 (d, J=3.1611 Hz,
10H), 1.4803 (s, 13H), 1.4180 (d, J=4.7853 Hz, 6H), .9487 (t, J=6.6377 Hz, 7H).
C43H69N13O9SNa+
2.2.2 Protein purification
2.2.2.1 Plasmid Prep
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Using pET28a-LIC we performed a plasmid prep. (EHMT1 (2IGQ) was a gift from Cheryl
Arrowsmith (Addgene plasmid # 25504; http://n2t.net/addgene:25504; RRID: Addgene_25504))
Agar plates were made using the formula 40 g LB Agar per 1 L DI water with 100 µL Kan
(Kanamycine Stock: 50 mg/ mL (1000x)).94 The LB agar was autoclaved and added to petri dishes
once allowed to cool down in the cold room so that it was cool enough to touch. Enough LB agar
was added to cover the bottom of the dish. The plate was removed from the cold room and allowed
to sit at room temperature (25°C) on the benchtop upside down to prevent condensation from
dripping onto the agar. Before streaking the LB Agar plate the pipettor and gloves were sprayed
with 70 % ethanol. To plate the bacteria a sterile pipette tip was stabbed in the bacteria and streaked
onto half of the plate. The tip was discarded, and the plate was rotated 90° before a new sterile
pipette tip was used to streak the plate a 2nd time overlapping a bit with the previously streaked
area of the plate. This was repeated once more so that the last quarter of the plate is also streaked.
After streaking the plate, the plate was placed upside down in the brown 37°C incubator to incubate
overnight.
Once distinct colonies have grown on the agar plate, we prepared four 8 mL culture tubes
with LB and the appropriate antibiotic. Before picking colonies the pipettor and gloves were
sprayed with 70 % ethanol. To inoculate he culture tubes a sterile pipette tip was stabbed into a
single colony and added into the culture tubes. Incubate at 37°C for 12-16 hours because pET28aLIC is a high copy plasmid.
2.2.2.2 PCR
Obtain a bucket with ice, a PCR kit box and remove the 2x Hot Start Master Mix Eppendorf. 94
the Nuclease Free water, the template DNA pET28a-LIC EHMT1, the 10 µM T7 Forward Primer,
and the 10 µM T7 Reverse Primer. Thaw everything on bench top at room temperature except the
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template DNA pET28a-LIC EHMT1, the 10 µM T7 Forward Primer and the 10 µM T7 Reverse
Primer which are thawed on ice. Add 13 µL nuclease free water is added with sterile pipette tips
to a PCR Eppendorf tube. Next add 25 µL of 2x Hot Start Master Mix to the PCR Eppendorf tube
and vortex to mix. Next add 10 µL of the Template DNA (pET28a-LIC EHMT1) to the Eppendorf
tube. Thereafter add 1 µL of both the 10 µM T7 Forward Primer and the 10 µM T7 Reverse Primer.
Vortex to mix well. We placed the PCR Eppendorf tube the Bio Rad T100 thermocycler we ran
the pre saved method labeled T7_PCR. T7_PCR’s cycling parameters are listed in table 1.

Segement Cycles Temperature
1
1
94
94
65
2
30
68
3
1
68
4
1
4

Time
30 seconds
30 seconds
1 minute
7 minutes
5 minutes
∞

Table 1. T7_PCR’s cycling parameters

In a separate Eppendorf tube, we added 40 μL of the PCR reaction mixture. Next, we added 5
volumes Buffer PB to 1 volume of the PCR reaction (200 μL of Buffer PB) and vortexed the
mixture. We placed a QIAquick column in a provided 2 mL collection tube. To bind DNA, the
sample was applied to the QIAquick column and centrifuged for 30–60 seconds. The flow-through
was discarded and the QIAquick column was placed back into the same Eppendorf tube. 750 μL
of Buffer PE was added to the QIAquick column and centrifuged for 30–60 seconds. We discarded
the flow-through and placed the QIAquick column back into the same tube. Then the the QIAquick
column was centrifuged once more in the 2 mL collection tube for 1 min to remove the residual
wash buffer. Then each QIAquick column was placed in a clean 1.5 mL microcentrifuge tube. To
elute the DNA, we added 50 μL of Buffer EB (10 mM Tris·Cl, pH 8.5) or water (pH 7.0–8.5) to
the center of the QIAquick membrane and centrifuged the column for 1 min. To increase DNA
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concentration, we added 30 μL of elution buffer to the center of the QIAquick membrane, let the
column stand for 1 min and then centrifuged. We checked the concentration of the protein using a
Thermo scientific Nanodrop 2000 spectrophotometer.
2.2.2.3 Transforming Cells
In a pre-chilled 1.5 mL microcentrifuge tube that is in ice we added the 2 µL of purified
plasmid of DNA directly into BL21 DE3 competent cells.94 The mixture was gently stirred and
quickly returned to ice, where it was let sit for 5 minutes. The cells were heat shocked in a hot
water bath at 42°C for 30 seconds. The cells were then allowed to sit on ice for 2 more minutes.
Next, we added 80 µL of room temperature S.O.C. medium. The microcentrifuge tube was shaken
at 250 rpm at 37°C for 60 minutes prior to being plated a on Kanamycin plate
In four 2 L culture flasks 47.6 g of Terrific Broth modified (TB) were dissolved in 1L of
di-ionized water by gently swirling. To each flask 4 mL of glycerol was added. The flasks were
covered with aluminum foil autoclave tape and then autoclaved for 15 minutes. After autoclaving
the flasks were stored at room temperature away from sun light.
2.2.2.4 Protein Purification
The cultures were poured into large centrifuge containers and balanced before being spun
down for 40 minutes at 1400 G’s.94 A small sample was taken before centrifugation so that it could
be compared to the sample after it has been centrifuged. Once the samples are finished centrifuging
a sample of the supernatant was taken and saved. The rest of the supernatant was poured off and
the pellets were scooped out, and resuspended in protease buffer with 50 mg of Lysozyme. This
mixture was let to sit for 30 minutes so that the Lysozyme was given time to work to break down
the cell wall. 5 µL of nuclease was added to break down DNA. This solution was sheered through
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a syringe to make sure there were no clumps before running it on the Avestin Emulsiflex C3 (also
referred to as French pressure cell press or French press). The pressed solution was put into
centrifuge tubes that were graded for over 5000 rpm rating and then balanced again. The samples
were centrifuged for 1 hour at 18000 rpm at 4°C. When finished another sample of the supernatant
was taken and saved. 2 mL of equilibrated beads suspended in protease buffer were added to the
samples and then shaken for 1 hour. The solution was loaded onto a Ni-NTA column and then
eluted off using varying concentrations of imidazole washes. The washes were performed with 0,
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Figure 3. 10% SDS page gel of the elutions from the Ni-NTA column. Elutions using a percent of elution buffer:
wash buffer. The elutions using between 40% and 100% elution buffer were considered pure, while the fractions
eluted off with 0% through 30% washes were considered impure.
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1 L: 20 mM Tris pH = 8.00, 250 mM NaCl, 5 % glycerol, and 50 mM imidazole. Elution Buffer
1 L: 20 mM Tris pH = 8.00, 250 mM NaCl, 5 % glycerol, and 250 mM imidazole.)
After this column was run, we deemed all of the fraction eluted with concentration between
40% and 100% enough via agarose electrophoresis gel. (Fig. 16) We also deemed the fractions
eluted between 0 and 30% not pure enough yet, but we would recolumn them to obtain more pure
protein. Both of these groups were put into dialysis bags and allowed to dialyze for 48 hours to
remove imidazole. The impure samples were recolumned after dialysis, while the pure samples
were concentrated using a Vivaspin 20 centrifugal concentrator run at 4950 rpm at 4°C for 15
minutes at a time. We got the pure EHMT1 solution down to a concentration of 228 µM 95 PDB:2IGQ
2.3 Noncompetitive Protein Pulldown Assay
We diluted a stock of Probe 3 to 10 nM using DMSO as well as diluting the EHMT1 stock to
228 µM. Solutions of Probe 3 and EHMT1 in PBS buffer with varying concentrations were made
and incubated in a warm water bath at 37°C for 10 minutes. The solution is then was irradiated in
a CL-1000 Ultraviolet Crosslinker while on ice at 365 nm for 1 hour. 8 While the samples irradiate
high-capacity streptavidin agarose resin beads were equilibrated in PBS buffer. Once the samples
have finished incubating the samples added to a protein concentrator and centrifuged at 14000 g
for 5 minutes, then 100 µL of PBS buffer were added and centrifuging was repeated. This step was
added to remove unbound probe so that it would not compete with the bound probe for the
streptavidin beads. To remove the protein-probe complex from the filter of the concentrator we
put the filter into a clean concentrator tube and centrifuge it at 1000 g for 2 minutes. Once the
beads were equilibrated and the samples were filtered, we would resuspend the samples in 16 µL
of PBS buffer add the samples to the beads and incubate for 1 hour on a Thermocycler shaking at
1500 rpm at room temperature. The samples were then spun down at 13000 rpm for 3 minutes at
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3°C and the supernatant was removed, and saved, and then 300 µL of PBS buffer was added to the
samples. The samples were then vortexed, and then this process was repeated twice more with the
supernatants being saved. 20 µL of 25 mM Biotin in BPS containing .4% SDS (w/v) was added to
each sample and then they were incubated at 95°C for 5 minutes while shaking on the
Thermocycler at 1500rmp or 10 minutes at 800 rpm at 95°C. The samples and all saved
supernatants from the three washes were then put onto a Supervac to reduce their volumes. They
were then resuspended in 10 µL of PBS with 5 µL of Laemmli buffer and heated at 100°C for 10
minutes. The samples were then added to a 10% SDS page gel for 70 minutes ate 120 Volts. The
gels were then analyzed using western blot procedure.
This same protein pull assay down method was completed with ADA in place of EHMT1. The
pure ADA that was used in these experiments was purchased from Sigma-Aldrich as a 10 mg/mL
(245 µM) stock solution.
2.4 Competitive Protein Pulldown Assay
The competitive assay is run with the same protocol as the noncompetitive protein
pulldown assay except instead of adding Probe 3 to the initial Eppendorf tubes SAM was added in
place of it and it was incubated for 5 minutes in the hot water bath at 37°C. After this Probe 3 was
added and the samples were incubated again at 37°C for 10 minutes. The rest of the assay is the
same as the noncompetitive protein pulldown assay.
The same competitive protein pulldown assay was completed ADA in place of EHMT1
and Inosine in place of SAM.
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3. Results & Discussion
3.1 Synthesis of Probe 1
In our initial synthetic plan (Figure 17), the synthesis of probe 1 started with commercially
available 8-bromoinosine. The 2', 3', and 5'-position hydroxyl groups were protected with acetic
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Figure 17. Synthetic scheme 1. This scheme was unsuccessful because the selective deprotection of the 5-position
acetyl group was unable to be performed
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Figure 18. The serendipitous synthesis of probe 3.

anhydride to afford intermediate 2 in 68.7% yield. The bromine in intermediate 2 can then be easily
replaced by azido group through nucleophilic substitution reaction with sodium azide in DMF at
100°C. This step resulted in the formation of intermediate 3 in 60.2% yield. Mono-protected 1,6diaminohexane was coupled with intermediate 3 under standard amide coupling condition using
PyBOP as the coupling agent. Intermediate 4 was thus obtained in 55.0% yield. The Boc protecting
group in intermediate 4 was removed with the treatment of TFA in dichloromethane, leading to
the formation of intermediate 5 in 79.5% yield. This deprotection step revealed a free amino group
which can then be coupled to biotin via another round of amide coupling reaction using EDCI as
the coupling agent. The second coupling reaction appended biotin to the core structure to afford
intermediate 6 in 62.0% yield.
In our original plan, the 5'-acetyl group in compound 6 could be selectively removed under
a previously described condition to form probe 2 (Figure 17). 6 This would allow the “warhead”
portion to be conjugated to the riboside through the 5'-position. However, this selective
deprotection was not successful. Instead of the desired mono-deprotected product, a monoprotected product, probe 3 (Figure 18), was obtained in 46.6% yield. The reaction conditions were
further modified to achieve the desired product. However, changing the reaction temperature (to 20°C or 0°C) or changing the stoichiometry of the reactants only led to significant and complex
decomposition of the starting material. Although not the desired compound, probe 3 was proven
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to be extremely useful for the establishment and optimization of the labeling and affinity
enrichment assay which will be discussed later in this chapter.
The unsuccessful initial synthetic efforts prompted us to seek an alternative synthetic route.
Scheme 2, seen in figure 19, also started with commercially available 8-bromoinosine, but the first
step was the protection of the 2' and 3'-position hydroxy groups on the ribose ring as an acetonide.
This reaction was carried out in a mixture of acetone and 2,2-dimethoxypropane with pNH
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Figure 19. Synthetic scheme 2. This scheme was successful in forming probe 1.
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toluenesulfonic acid (p-TsOH) as the catalyst. Intermediate 1 was obtained in 83.5% yield. The 5'position hydroxyl group in intermediate 1 was, once again, protected with acetic anhydride to
afford intermediate 2, with an obtained yield of 99.4%. The fully-protected 8-bromoinosine
derivative, intermediate 2, was then subjected to the nucleophilic substitution using sodium azide
to form intermediate 3 in nearly 82.9% yield. Intermediate 3 was then coupled to mono-N-Boc1,6-diaminohexane, followed by Boc deprotection and coupling to biotin. The reaction conditions
of these three steps were similar to the ones in synthetic plan 1. They gave decent to good yields,
leading to the formation of intermediate 6. The selective deprotection of the 5'-position acetyl
group was straightforward using ammonia in methanol at -40°C. The successful selective
deprotection resulted in the formation of probe 4 in 79.9% yield. The free hydroxyl group in probe
4 was activated as a mesylate by reacting with methanesulfonyl chloride (MsCl) in the presence
of trimethylamine (TEA). Intermediate 7 was obtained in 35.0% yield. Mesylate 7 was used for
the next step without further purification. The amination of 7 using methylamine led to the
formation of intermediate 8. A reductive amination between intermediate 8 and tert-butyl (S)-2[N-(tert-butoxycarbonyl) amino]-4-oxobutanoate (compound 9) in the presence of NaBH 3CN and
acetic acid led to the formation of an advanced intermediate 10 in 22.9% yield. Ultimately, the
global deprotection of intermediate 10 will give rise to probe 1. As of now, we are still in the
process of optimizing the reaction conditions of the final step.
3.2 EHMT1 Expression and Purification
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When we obtained our pET28a-LIC vector we attempted to transfect a Rosetta DE3 cell
line. The Rosetta DE3 cells did not grow, forcing us to use another cell line for this transformation.
The second cell line we used was the BL21 DE3, and these cells grew and were cultured
successfully.96 These cells were then lysed, the this was then cells were pelleted. The pellets were
separated from the cell supernatant, resuspended in buffer and then lysozymes and nucleases were
used to break down excess cell wall and DNA respectively. This was then sheared using a syringe
and the emulsiflex. This solution was then equilibrated with nickel beads, to allow for the histagged EHMT1 to bind. This was then loaded onto a column and was washed with a wash solution
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Figure 20. 10% SDS page gel of the elutions from the Ni-NTA column. Elutions using a percent of elution
buffer: wash buffer. The elutions using between 40% and 100% elution buffer were considered pure, while the
fractions eluted off with 0% through 30% washes were considered impure.
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used to elute off the bound EHMT1 off of the column. The samples were resolved using SDSPAGE gel.
3.3 Photoaffinity Labeling and Affinity Enrichment of EHMT1 Assay
In parallel to the synthesis, we also dedicated efforts to establish and optimize the photoaffinity
labeling and the subsequent affinity enrichment assay using synthetic probes. With probe 1 still in
the making, we used probe 3 for the assay development.
3.3.1 Optimization of Irradiation Time
SAM-based probe 3 targets the active sites of MTases. When the photoactivatable azido group
of the probe is in the vicinity of the protein and is UV irradiated, the two become covalently
conjugated. The irradiation time was optimized first. In this study, a 365 nm UV lamp was used
because optimal photocrosslinking was observed for aryl azide at this wavelength as suggested by
the literature.8 500 µM of Probe 3 was incubated with recombinant EHMT1 10.26 µM for 10 min.
Subsequently, the samples were irradiated with varying amounts of time (from 15 min to 90 min)
at 365 nm. The samples were then resolved by SDS-PAGE and analyzed by western blot using an
anti-biotin antibody (Fig. 21). The labeling was detected after merely 15 min’s irradiation. And
the labeling intensity reached plateau within 60 min.
With this knowledge moving forward all photocrosslinking experiments were completed with
a 60-min irradiation time.
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Figure 21. Western blot of time dependent
binding. We see the bands get darker as
irradiation time increases, but hits a peak at
60 minutes.

3.3.2 Optimization of Probe Concentration
Following the optimization of the irradiation time, the concentration of the probe was also
optimized. To determine the most optimal concentrations of the probe, EHMT1 was incubated
with varying concentrations of probe 3 (0, 25, 50, 125, 250 or 500 M) and then irradiated at 356
nm for 60 min. The samples were then resolved by SDS-page gel and analyzed by western blot
(Fig. 22). Probe 3 was able to label recombinant EHMT1 in a concentration-dependent manner.
Below 250 M, there were negligible levels of labeling. The labeling started to be detected at 250
M concentration, and intensified at 500 M dosage. For the following affinity enrichment assay,
only concentrations higher than 250 M were used.
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Figure 22. Western blot from concentration dependent study. Bands become visible at 250 µM of
probe 3. This band became more intense as probe 3 concentration was increased to 500 µM. Seeing
a lack of bands in 25 µM, 50 µM, and 125 µM concentrations of probe 3 led us to believe this
concentration was too low to label EHMT1, and following this study we did not run concentrations
of probe lower than 250 µM.

3.3.3 Improvement of Enrichment and Elution
Following the concentration-dependent study, we attempted to run our first complete pulldown assay. EHMT1 was incubated with 0, 250, or 500 M probe 3 before being irradiated for 60
min. After photocrosslinking, the samples were incubated with streptavidin beads for 1 hour on a
shaker to allow the biotinylated proteins to be captured by the beads. The supernatants containing
unbound proteins were then separated from the beads. After thorough rinsing, the EHMT1-Probe
3 complex was then eluted off of the beads with a 2 mM solution of biotin in PBS buffer. The
samples were then resolved by SDS-PAGE and analyzed by western blot using an anti-biotin
antibody. From this experiment we saved every wash, elution, and the beads to determine if the
probe protein complex was lost during any step.
Figure 23 illustrates the western blots from the pull-down experiment. At both 250 and 500
M concentrations, biotinylated EHMT1 was detected in a concentration-dependent fashion in the
elutions, albeit at relatively low intensity. However, significant amount of labeled EHMT1 was
64

detected in the supernatants and on the beads, suggesting that not all the biotinylated proteins were
captured and not all captured proteins were completely eluted off. To improve the capture capacity,
the incubation time of EHMT1-probe 3 complex with the beads was increased from 1 h to 3 h. To
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Figure 23. A. The elution gel we see faint bands in the 250 µM and 500 µM of concertation of probe
3. B. The supernatant gel 1 with the 250 µM concentration of Probe 3 sample. The dark band here is
problematic because all EHMT1-probe 3 complex should have bound to the streptavidin beads, and
the same goes for C. The supernatant gel 2 with the 500 µM concentration Probe 3 sample. D. The
beads gel also has dark bands on it where it should not. We would have expected all EHMT1-probe 3
complex to have eluted off of the streptavidin beads during the elution wash.
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improve elution efficiency, the concentration of biotin in the elution solution was increased from
2 mM to 25 mM. These modifications greatly improved the affinity enrichment and elution
because almost all the labeled EHMT1 was captured and almost completely eluted off of the beads.
3.3.4 Pull-down Assay Lacking a Filtration Step
A revised version of the complete pull-down assay was performed including optimized
irradiation time, optimized probe concentrations, improved enrichment and elution strategies.

Figure 24. The experiment without a filtration step. The top bands that we see are at 37 KDa and the
bottom bands are where the gel was allowed to run down to. We see band intensity increase as
Probe 3 concentration increases which is promising,

66

EHMT1 was incubated with probe 3 and irradiated for 1 h at 365 nm. Streptavidin beads were then
introduced into the samples for 3 h’s incubation. Subsequently, the supernatants containing the
unbound proteins were removed. The beads were thoroughly rinsed with buffer and then incubated
with elution buffer containing 25 mM biotin. The eluted samples were resolved by SDS-PAGE
and analyzed by western blot as described above.
Concentration-dependent labeling and enrichment of EHMT1 was observed in the elution
samples (Fig. 24.). However, in addition to the biotinylated EHMT1 (~37 kDa), another band
running close to the bottom of the blot was also detected. We reasoned that the lower running band
was most likely the free probe 3. In the initial incubation, high micromolar concentrations of probe
3 were used. Some of the unbound probes were carried over to the elution samples. This can be
problematic because the free probes could compete with the biotinylated proteins for binding to
reduce the efficiency of the enrichment. To reconcile this, after the photoaffinity labeling, a
filtration step was added to remove the free probes. Centrifugal filter units with 10 kDa cutoff were
used to eliminate the small molecules, but to retain the proteins. After the filtration, the samples
were subjected to the affinity enrichment as described above.
3.3.5 Optimized Pull-down Assay
After the above-mentioned alterations and adjustments, an optimized photoaffinity labeling
and affinity enrichment assay was established. Briefly, the synthetic probe was incubated with
EHMT1. After 1 h’s UV irradiation, the samples were filtered to remove unbound probes. The
filtered samples were then incubated with high-capacity streptavidin beads. Unbound proteins
were separated from the beads. After thorough rinsing, the beads were incubated with excess
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E 0µM

E 250µM
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Figure 25. Affinity enrichment assay. L was the protein ladder to make sure the gel ran to
completion. E 0 µM is a protein standard, we expect to see no band in this lane because EHMT1
does not have biotin tag for anti-biotin antibodies to bind to. E 250 µM has that concentration of
Probe 3 present in the solution. We see a band here meaning probe 3 has covalently bound to
EHMT1 via photocrosslinking. The band at E 500 µM is for probe 3 concentration is darker than
the 250 µM implying the increased concentration led to increased binding. Finally, the ES is the
enzyme standard lane.

amount of biotin to dissociate the proteins from the beads. Finally, the elutions were analyzed by
western blot as mentioned previously.
Figure 25 shows a western blot for an optimized pull-down assay. Probe 3 labeled EHMT1 in
a dose-dependent manner, as evidenced by the bands at ~37 kDa. More importantly, the lower
running bands corresponding to the unbound probe were not detected, suggesting the successful
removal of these small molecules from the samples. Additionally, biotinylated proteins were not
observed in supernatants, washes or on the beads, further proving the effective enrichment and
elution.
Taken together, the photoaffinity labeling and enrichment assay using SAM-based chemical
probes has been established and optimized. Probe 3, indeed, labeled EHMT1, although at high
micromolar concentrations (no less than 250 M). The relatively weak affinity of probe 3 to MTase
stemmed from its structural features. Probe 3, lacking the “warhead” portion, is an adenosine
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analog rather than a SAM derivative. We hypothesized that probe 3 would prefer to bind to
adenosine binding proteins, and probe 1, a true SAM analog, would have a higher affinity to
MTases. This type of selectivity is ideal for probe development.
3.4 Pull-down Assay Using an Adenosine Binding Protein
Adenosine deaminase (ADA) was used for the following experiments. ADA is an enzyme that
catalyzes the deamination of adenosine into inosine.97 A deficiency in ADA in humans leads to tlymphocyte development deficiency.98 In addition to ADA being a well-known adenosine binding
protein it is also commercially available. Being commercially available allows us to save time
skipping the protein purification.

A

B

Figure 26. Chemiluminescence western blot images of the affinity enrichment gels. A) is a competitive
binding of Probe 3 competing with inosine binding to ADA. B) is a competitive binding of Probe 3
competing with SAM binding to EHMT1. The lanes labeled L were where the ladder was run. Lanes
labeled with concentration are stating the concentration of Probe 3 present in that sample.
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Recombinant ADA was incubated with probe 3 at various concentrations (0, 25, 50, 125, 250
or 500 M) before being irradiated at 365 nm for 1 h. After removal of free probes using centrifugal
filter units, the samples were incubated with streptavidin beads for affinity capture. The
supernatants were then removed, and the beads were rinsed and incubated with biotin elution
buffer. The eluted proteins were analyzed by immunoblotting (Fig. 26.). Probe 3, as expected,
demonstrated higher affinity to ADA. It labeled this protein in a nice concentration-dependent
manner. Even at the lowest concentration, 25 M, the labeling could still be detected.
3.5 Competitive Labeling Assay
One of the major issues in photoaffinity labeling is the non-specific labeling which may create
background noise or false positive results. In order to rule out the possibility of off-target effect,
competition analysis using known EHMT1 or ADA inhibitors was also performed. SAM, the
endogenous co-substrate of MTases, was used as the competitor for EHMT1. The protein was
incubated with SAM before the addition of probe 3. Subsequently, the samples were subjected to
the filtration, capture, rinsing and elution protocols as described before (Figure 27. A). With probe
3 alone, EHMT1 was labeled in a concentration-dependent manner, consistent with prior results.

A
Probe 3 (µM)
Competitor (µM)
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250

250

0
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Figure 27. A. Western blot we obtained from the competitive pull-down assay with Probe 3 and EHMT1. A faint band is
observed with 250 µM of Probe 3 in the absence of the competitor SAM. In the presence of ten times concentration of SAM
the 250 µM of Probe 3 is out competed and the band disappears. The band intensity at 500 µM of Probe 3 is more intense,
but again when ten times concentration of the competitor is added the band disappears. B. Western blot we obtained from
the competitive pull-down assay with Probe 3 and ADA. A faint band is observed at 12.5 µM of Probe 3, but when 10 times
concentration of competitor cladribine is present the band again disappears.
70

The introduction of excess amounts of SAM, the labeling o EHMT1 by probe 3 was almost
completely abolished, suggesting the on-target activity of our probe.
For ADA, a known inhibitor, cladribine,99,93 was chosen for the competitive labeling
experiments. Cladribine is a purine analog that is resistant to ADA breakdown, this causes it to
accumulate in cells. Probe 3 alone at 12.5 M demonstrated robust labeling of ADA (Figure 27,
B). In the presence of 10 times excess amount of cladribine, the labeling was significantly reduced,
once again suggesting the on-target effect of the synthetic probe.
3.6 Spiked in Cell Lysate Labeling

Figure 28. In the first lane we have an ADA standard to show what where on the blot we would expect
to see our pulled down protein to be at. With 0 µM of Probe 3 we still see some protein being pulled
down, we can attribute this to proteins that bind naturally to streptavidin beads. With the addition of 5
µM of Probe 3 we see a faint band appear where we could expect ADA to be on the blot. With 10 µM of
Probe 3 the band is now very intense where we would expect to see ADA on the blot.
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We wanted to make sure we could use this protein pull-down to see if we could separate a
specific type or protein from a cell lysate. For this experiment we spiked in 10 µM of ADA into
the cell lysate from the EHMT1. We incubated probe 3 with the cell lysate and then performed
and then irradiated it for 3 hours. We then loaded these samples onto the SDS-page gel and ran
western blot procedures to obtain our blot.
In Figure 28 we see the blot obtained from the spiked in protein cell lysate affinity labeling
assay. We ran a lane with pure ADA to show where the band would be present so that we could
see it in comparison to other bands that might be present. We see some protein noise that is present
from the cell lysate in lane with 0 µM of probe 3. In lane with 5 µM of probe 3 we see a faint band
where we would expect the ADA band to be. The lane with 10 µM of probe 3 we see a very distinct
intense band. This leads us to believe that we can selectively pull-down proteins that our probes
bind to.
3.7 Conclusion
This project aimed to synthesize probe 1 and create an assay for the profiling of MTases.
We synthesized an intermediate of probe 1, probe 3. Studying the biological activity of probe 3
will provide us an important understanding of how we expect probe 1 to function when it is
successfully synthesized. We optimized a protein pull-down assay to study the activity of probe 3
using both a MTase and an adenosine binding protein. We have determined that probe 3 was able
to bind to our model MTase EHMT1. Following this we completed a competition assay using
SAM as a competitor to rule out photocrosslinking caused by nonspecifically interacting between
probe 3 and EHMT1. Due to requiring a high concentration of probe 3 to pull-down EHMT1 we
used an adenosine binding protein, ADA, to show probe 1 should have a higher affinity when
completed. We preformed the same pulldown and competitive assays with ADA as we had with
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EHMT1. From these studies we found that probe 3 would bind to ADA at a much lower
concentration that it would to EHMT1, we reasoned that this must occur because probe 3 is an
adenosine analog not a SAM analog. In our final experiments we performed protein labeling with
ADA spiked into cell lysate. We saw that we were able to selectively separate ADA from the cell
lysate. This means in the future we should be able to use probe 1 to selectively pull-down MTases
from their endogenous cell lysate.
A future study we would like to perform a protein pull-down using a MTase at its
endogenous concertation. An additional study that could be completed to improve our probe would
be to perform a docking analysis. We could attempt to further optimize the positions of the azide
photocrosslinking group as well as linker region containing the biotin tag to improve binding to
MTases. Finally, a proteomic profiling study will be completed by Dr. Stan Steven from the
University of Southern Florida in the future to determine if our probes will bind to any other
proteins.
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4. NMR Spectrums
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